Vanda Pharmaceuticals | VNDA - Zinsaufwendungen Für Schuld





Zinsaufwendungen Für Schuld Veränderung Datum
Acadia Pharmaceuticals USD 0 4.12M 2024-09
Agios Pharmaceuticals USD 1.11B 76.57M 2026-06
Akebia Therapeutics 349.66M 12.86M 2026-06
Alnylam Pharmaceuticals USD 82.05M 12.76M 2026-06
Anika Therapeutics 183.47M 4.09M 2026-06
Arrowhead Research USD 24.56M 716K 2026-06
AstraZeneca USD 340M 144M 2026-06
Bristol-Myers Squibb USD 407M 4M 2026-06
Eli Lilly USD 114.7M 134.3M 2025-09
Enanta Pharmaceuticals USD 1.96M 620K 2024-12
Halozyme Therapeutics USD 5.59M 80K 2026-06
Heron Therapeutics USD 600K 100K 2024-12
Insmed USD 18.84M 1.24M 2026-06
J&J USD 43M 25M 2026-03
Lexicon Pharmaceuticals USD 2.03M 124K 2025-12
Ligand Pharmaceuticals USD 1.78M 875K 2025-12
Merck USD 525M 46M 2026-06
Minerva Neurosciences USD 2.31M 60K 2024-06
Moderna USD 10.96B 527M 2026-06
Novartis USD 281M 8M 2025-09
Pfizer USD 667M 4M 2026-06
PTC Therapeutics USD 3.25B 381.37M 2026-06
Puma Biotechnology USD 3.37M 11K 2024-06
Sangamo BioSciences 97.56M 11.39M 2025-06
Sanofi EUR 287M 109M 2026-06
Takeda JPY 63.85B 20.2B 2026-06
Teva Pharmaceutical Industries USD 195M 21M 2026-06
Ultragenyx Pharmaceutical USD 22M 1000K 2026-06
Vanda Pharmaceuticals -1.37B 1.97B 2025-12
Veracyte USD 2K 1000 2023-12